[Assessment of the selected, late phase of angiogenesis factors' concentration in colorectal cancer patients].

Angiogenesis is a process of new blood vessels creating based on existing already vascularisation. This composed and multistage mechanism, which is responsible for growth of the tissues and organs, plays a crucial role in neoplasia. The exact role of particular cells, cytokines and extracellular matrix in cancerogenesis is still discussing. An identification of it is the key to searching the antiangiogenic substances breaking simultaneously neoplastic proliferation. THE AIM OF THE STUDY was to compare the angiopoietin-1(Ang-1), angiopoietin-2 (Ang-2) and Tie-2 receptor (rec. Tie-2) concentrations in the serum of colorectal cancer patients with concentrations of these factors in the serum of healthy people. Moreover the aim of the study was to assess the correlation between the concentrations of these factors and stage of clinical neoplasm progression.
The study included 35 patients hospitalized in the Department of General Surgery due to confirmed by histopatological examination colorectal cancer, between 2006 to 2007. The group of examined patients consisted of 9 women and 26 men with ages between 39 to 81 (average 67.20+/-8.85). The control group consisted of 11 healthy people. The examinations relied on the 10 ml of blood sampling from all the patients, in fasting state, one day before the operation. 10 ml of blood, in the healthy group was also sampled in fasting state. Afterwards all blood samples, 30 minutes after collecting, were centrifuged with velocity 6000 rotation per minute. The gaining serum was freezed in temperature -80 degrees C. The concentrations of Ang-1, Ang-2 and rec.Tie-2 were measured with ELISA method.
Among examined patients with colorectal cancer, the statistically significant, higher concentration of Ang-2 in comparison with control group was revealed (6239.7+/-3482.3 pg/ml vs. 2954.9+/-9624.2 pg/ml). The concentration of Ang-2 among the patients from III and IV group according to the clinical and pathomorfological progression classification was statistically significant, higher than in I and II group of the patients (III: 8668,8+/-4938.57 pg/ml; IV: 9002.1+/-5380.92 pg/ml vs. I: 4672.3+/-1808.7 pg/ml; II: 5284.8+/-3204.2 pg/ml). The concentration of Ang-1 and rec. Tie-2 in blood of all the patients with colorectal cancer didn't statistically differ from the control group (Ang-1: 42339.9+/-20197.2 pg/ml vs. 48976.4+/-2284.5 pg/ml; rec.Tie-2; 14.4+/-5.1 vs. 16.8+/-6.2 ng/ml).
The concentration of Ang-2 in the colorectal patients was statistically higher than in the control group. The increase concentration of Ang-2 correlated with the stage of colorectal cancer's clinical progression. The higher concentration of Ang-2 may eventually become a helpful marker in diagnostic and assessment of colorectal cancer's clinical progression stage.
AuthorsMaria Wieloch, Magdalena Swiatkowska, Michał Libiszewski, Masoud Hedayati, Rafał Drozda, Krzysztof Kołomecki
JournalPolski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego (Pol Merkur Lekarski) Vol. 27 Issue 162 Pg. 466-9 (Dec 2009) ISSN: 1426-9686 [Print] Poland
Vernacular TitleOcena stezenia wybranych czynników poznego etapu angiogenezy u chorych na raka jelita grubego.
PMID20120708 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Angiopoietin-1
  • Angiopoietin-2
  • Biomarkers, Tumor
  • Receptor, TIE-2
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiopoietin-1 (metabolism)
  • Angiopoietin-2 (metabolism)
  • Biomarkers, Tumor (metabolism)
  • Colorectal Neoplasms (metabolism, pathology)
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Receptor, TIE-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: